Filing Flows › Boston Scientific (BSX) › How it makes money
How Boston Scientific (BSX) makes money
Boston Scientific (BSX) made $5.1B of revenue in the third quarter 2026 (Q3 2026), +1% from a year earlier. Interventional Cardiology & Vascular Therapies brought in $1.3B (25%); Electrophysiology brought in $816M (16%); Endoscopy brought in $741M (14%). Of every dollar of revenue, 67¢ was left as gross profit, 16¢ was left as operating profit, 11¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | $1.3B | 24.8% | -5% | +12% |
| Electrophysiology | $816M | 15.9% | -11% | -6% |
| Endoscopy | $741M | 14.4% | -7% | -0.8% |
| Urology | $661M | 12.9% | -3% | -3% |
| Cardiac Rhythm Management | $568M | 11.1% | -3% | -2% |
| Watchman | $482M | 9.4% | -5% | -6% |
| Neuromodulation | $331M | 6.4% | -3% | +13% |
| Interventional Oncology & Embolization | $267M | 5.2% | -6% | +6% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $5.1B | 100.0% |
| Cost of revenue | $1.7B | 33.3% |
| Gross profit | $3.4B | 66.7% |
| Operating expenses | $2.6B | 50.6% |
| Operating profit | $828M | 16.1% |
| Income tax | $153M | 3.0% |
| Net earnings | $580M | 11.3% |
| Operating cash flow | $1.0B | 20.4% |
| Free cash flow | $868M | 16.9% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $5.1B | +1% |
| Q2 2026 | $5.4B | +8% |
| Q1 2026 | $5.2B | +12% |
| Q4 2025 | $5.3B | +16% |
| Q3 2025 | $5.1B | +20% |
| Q2 2025 | $5.1B | +23% |
| Q1 2025 | $4.7B | +21% |
From Boston Scientific's 10-Q filed Nov 2, 2026 (on EDGAR).
Questions
How does Boston Scientific make money?
Boston Scientific (BSX) made $5.1B of revenue in the third quarter 2026 (Q3 2026), +1% from a year earlier. Interventional Cardiology & Vascular Therapies brought in $1.3B (25%); Electrophysiology brought in $816M (16%); Endoscopy brought in $741M (14%). Of every dollar of revenue, 67¢ was left as gross profit, 16¢ was left as operating profit, 11¢ was left as net earnings.
What is Boston Scientific's biggest business?
Interventional Cardiology & Vascular Therapies: $1.3B in the third quarter 2026, 25% of revenue, +12% from a year earlier.
What is Boston Scientific's profit margin?
Net earnings were $580M, 11.3% of revenue, in the third quarter 2026; the operating margin was 16.1%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.